2025-06-12-Jefferies-ADA25摘要对我们覆盖范围及约10个关键可比公司的ADA初探_17页_10mb

ADA25 Abstract Summary: A First Look Into ADA from Our Coverage and ~10 Key Comps

Core Content Overview

ADA25 featured a range of abstracts and presentations across multiple therapeutic areas, including obesity, Type 1 Diabetes (T1D), and other metabolic diseases. The event included both clinical and preclinical studies, with a focus on GLP-1 receptor agonists (incretin therapies), non-incretin compounds, and T1D-related research. Key highlights include significant weight loss (WL) outcomes, improved metabolic parameters, and exploration of novel mechanisms and combination therapies.

Main Incretin Compounds

Clinical Incretin Compounds

• Orfo Symposium: Ph3 ACHIEVE-1 full data on Orforglipron, a small nonpeptide GLP-1RA, presented on Saturday 8:40 am CDT.
• MariTide Symposium: Ph2 52W obesity (with and without T2D) full data, presented on Monday 1:30 pm CDT.
• ASC30: Phase 1a full SAD data presented on Sunday 12:30 pm CDT.
• MET097i: Phase 1 PK data and Phase 2a 12W obesity data presented on Sunday 12:30 pm CDT. MET-097 demonstrated up to 11.3% WL with titration-free weekly dosing.
• RGT-075: Phase 2a 12W obesity data presented on Sunday 12:30 pm CDT. RGT-075 achieved ~5% WL with robust blood pressure changes.
• NVO (CagriSema): REDEFINE 1 and 2 data presented on Sunday 8:00 am CDT. CagriSema showed significant WL in T1D and obesity.
• Amycretin: Phase 1b/2a data presented on Sunday 12:30 pm CDT. Subcutaneous administration resulted in up to 23.2% pbo-adj WL at 36W.
• Petrelintide: Phase 1 data presented on Sunday 12:30 pm CDT. Demonstrated clinically relevant reductions in BW and WC, with better response in women.
• Azelaprag: Preclinical data on glycemic control and WL in diabetic obesity models, presented on Saturday 12:30 pm CDT and Sunday 12:30 pm CDT. Demonstrated significant WL and combination benefits with tirzepatide.
• MET-233: Preclinical data presented on Sunday 12:30 pm CDT. MET-233i showed similar WL effects to MET-097 and CagriSema, with additive benefits in combination.

Preclinical Incretin Compounds

• GPCR: Oral small molecule GLP-1R agonist showed neuroprotective effects in MPTP-induced PD model, improving motor deficits and preserving DA neurons.
• ACCG-2671: Demonstrated significant, dose-dependent WL in DIO rats. Combination treatments showed superior outcomes compared to monotherapy.
• GUBamy: Presented in Phase 1 SAD trial, with promising WL and safety data.
• ASC47: Preclinical data showed superior WL than sema mono in DIO with indication of muscle preservation.
• AZD6234: Combined treatment with semaglutide showed additive effects on food intake suppression, BW, and fat mass loss in DIO rats.
• PSTC1201: Demonstrated WL and improved body composition when combined with semaglutide in DIO mice.

Main Non-Incretin Compounds

Clinical Non-Incretin Compounds

• MYO4: First-in-class antibesogenic and muscle-preserving small molecule metabolic modulator presented on Sunday 12:30 pm CDT.
• Bimagrumab: Symposium on the BELIEVE study, which combines bimagrumab with semaglutide to enhance fat-specific WL and preserve lean mass.
• Icovamenib: Phase 1 data showed WL and improved body composition in DIO models, with additive effects when combined with semaglutide.
• HM17321: Demonstrated WL and improved body composition in DIO models, with additive effects when combined with HM15275.
• Ecnoglutide: Phase 3 evaluation in overweight or obesity, presented on Sunday 12:30 pm CDT.
• VRB101: Phase 1a data on an oral GLP-1RA with once-weekly dosing potential, presented on Sunday 12:30 pm CDT.
• HDM1002: Phase Ib study in Chinese adults with overweight or obesity, presented on Sunday 12:30 pm CDT.
• Ehsabaglutide Alfa: Phase 2 data on efficacy and safety in obesity, presented on Sunday 12:30 pm CDT.
• LEA102: First-in-human study on safety, tolerability, and pharmacodynamics, presented on Sunday 12:30 pm CDT.

Preclinical Non-Incretin Compounds

• BGM1812: Novel amylin analog showed superior WL in preclinical models.
• DA-1241: GPR119 agonist demonstrated additive hepatoprotective effects when combined with efruxifenm in DIO and MASH models.
• BI-4659: Mitochondrial uncoupler reversed DIO in mice.
• ECC4703: Liver-targeting THRb agonist showed enhanced WL and glycemic control when combined with semaglutide and tirzepatide.
• PTT-A: Unimolecular peptide tetra-agonist targeting multiple receptors showed superior WL vs. tirzepatide in DIO rats.
• NN1213: Amylin receptor agonist reduced food intake and BW in rats.
• AZD6234: Long-acting amylin analog enhanced WL and fat mass loss when combined with semaglutide in DIO rats.
• Nimacimab: Peripherally restricted CB1 inhibitor promoted metabolic homeostasis in DIO models, with WL, restored hormonal regulation, and reduced inflammation.
• TLC1180: De novo or sequential combination with semaglutide improved WL and preserved lean mass in DIO mice.
• SRK-439: Anti-myostatin antibody improved grip strength in GLP-1RA-treated DIO mice.

T1D Research Highlights

• SANA Symposium: 6M follow-up data on UP421 from a single T1D patient, including C-peptide measurements and MMTT results.
• VRTX (VX-880): Presented in both oral and symposium formats. VX-880 showed durable glycemic control and elimination of exogenous insulin use in T1D patients.
• GentiBio (GNTI-122): A clinic-ready Treg therapy with stabilized FOXP3 and islet-specific TCR, aimed at halting T1D progression.
• LLY (Tirzepatide): Presented in an oral format, with data from a UK center on safety, tolerability, and clinical outcomes in T1D.
• Academic Research: Multiple preclinical studies explored novel approaches, including targeting IL-8/CXCR1-CXCR2 to unleash regulatory B cells and mRNA immunotherapy for T1D prevention.
• NextCell Pharma (ProTrans): Repeated infusion of mesenchymal stromal cell product slowed T1D progression and provided wider health benefits.
• Avotretes (AVT001): Two-year follow-up on dendritic cell therapy for T1D, with continued off-therapy functional effects and responder characterization.
• SNY (Teplizumab): TN-10 extension study presented on Sunday 12:30 pm CDT, focusing on prevention of T1D progression.

Key Events and Information

• Posters Available: Approximately 120 relevant posters/presentations are available, with an excel planner provided upon request.
• KOL Dinner: Scheduled for Sunday, June 22, 5pm - 7pm CDT at ADA.
• Posters on June 20th: Included siRNA-INHBE data, showing improved healthy WL profile and reduced pro-inflammatory lipidomic signatures.
• Posters on June 21st: Covered preclinical data on multiple compounds, including GUBamy, AZD6234, and others, with a focus on WL and metabolic benefits.
• Posters on June 22nd: Featured a wide range of clinical and preclinical data, including full data from Ph3 and Ph2 trials, and Phase 1 studies.

Key Takeaways

• Incretin Compounds: Showed significant WL, with some demonstrating superior outcomes in combination with other therapies.
• Non-Incretin Compounds: Demonstrated WL, muscle preservation, and cardioprotective effects in preclinical models.
• T1D Research: Focused on islet transplantation, immunotherapies, and novel therapies to reduce or eliminate exogenous insulin use.
• Data Types: Included preclinical, Phase 1, Phase 2, and Phase 3 data, with a mix of oral, subcutaneous, and combination therapies.
• Mechanisms: Explored GLP-1R agonism, amylin receptor agonism, dual receptor agonism, and other novel targets.

Summary of Key Abstracts and Presentations

Conclusion

ADA25 provided a comprehensive overview of ongoing and emerging therapies for obesity and T1D. The event emphasized the potential of GLP-1R agonists, non-incretin compounds, and combination therapies in improving weight loss, metabolic control, and disease progression. The data presented support continued interest in these therapeutic areas, with a focus on safety, tolerability, and mechanism of action.